SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03874455

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Patients with following conditions are eligible to enroll in the EAP: - Epithelioid Sarcoma (ES) - Spindle cell sarcoma - Sinonasal carcinoma - Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) - Thoracic sarcoma - Poorly differentiated chordoma These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed above are not eligible for the tazemetostat EAP

NCT03874455 Epithelioid Sarcoma Spindle Cell Sarcoma Sinonasal Carcinoma Smal Small Cell Carcinoma of the Ovary Hypercalcemic Type Thoracic Sarcoma Poorly Differentiated Chordoma
MeSH:Carcinoma Sarcoma Chordoma Carcinoma, Small Cell Small Cell Lung Carcinoma Carcinoma, Ovarian Epithelial
HPO:Carcinoma Chordoma Sarcoma Small cell lung carcinoma Soft tissue sarcoma

1 Interventions

Name: Tazemetostat

Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Type: Drug



There is one SNP

SNPs


1 V617F

JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---



HPO Nodes


HPO:
Protein Mutations 1
V617F
SNP 0